Additional data on measles virus antibody and antigen in subacute sclerosing pan encephalitis

Neurology ◽  
1968 ◽  
Vol 18 (Issue 1, Part 2) ◽  
pp. 087-90 ◽  
Author(s):  
J. H. Connolly
Keyword(s):  
Measles Virus ◽  
Additional Data ◽  
Virus Antibody

MEASLES-VIRUS ANTIBODY AND ANTIGEN IN SUBACUTE SCLEROSING PANENCEPHALITIS

The Lancet ◽  
1967 ◽  
Vol 289 (7489) ◽  
pp. 542-544 ◽  
Author(s):  
J.H. Connolly ◽  
IngridV. Allen ◽  
L.J. Hurwitz ◽  
J.H.D. Millar
Keyword(s):  
Measles Virus ◽  
Subacute Sclerosing Panencephalitis ◽  
Virus Antibody

Measles and Acute Glomerulonephritis

PEDIATRICS ◽  
1983 ◽  
Vol 71 (3) ◽  
pp. 398-401
Author(s):  
Ching-Yuang Lin ◽  
Hey-Chi Hsu
Keyword(s):  
Immune Complex ◽  
Measles Virus ◽  
Virus Antigen ◽  
Normal Serum ◽  
Acute Glomerulonephritis ◽  
Virus Antibody ◽  
Dense Deposits ◽  
Complex Deposition ◽  
Properdin Factor B ◽  
Classic Pathway

A 5-year-old boy had transient glomerulonephritis following measles infection. Serologic studies at the early onset of the disease showed decrease of serum C3, C4, and Clq levels with normal serum properdin factor B. Renal glomerular histology revealed a mild acute proliferative glomerulonephritis. Measles virus antigen, C3, C4, and immunoglobulin G (IgG) were demonstrated in the glomerulus, suggesting an immune complex deposition. Ultrastructurally, subepithelial, intramembranous, and subendothelial electron-dense deposits were noted, suggesting a postinfectious immune complex glomerulonephritis. It is suggested that the measles virus antibody complexes are deposited in the glomerulus and activate the classic pathway of complement, leading to a self-limited glomerulonephritis.

Modified seroneutralization assay for measles virus antibody detection

1994 ◽  
Vol 145 ◽  
pp. 45-49 ◽  
Author(s):  
S.V. Nates ◽  
G.Y. Rey ◽  
M.O. Giordano ◽  
M.T. Zapata ◽  
A. Depetris ◽  
...  
Keyword(s):  
Measles Virus ◽  
Antibody Detection ◽  
Virus Antibody

Intra-blood-brain barrier measles virus antibody synthesis in multiple sclerosis patients

Neurology ◽  
1983 ◽  
Vol 33 (1) ◽  
pp. 45-45 ◽  
Author(s):  
P. Albrecht ◽  
W. W. Tourtellotte ◽  
J. T. Hicks ◽  
H. Sato ◽  
E. J. Boone ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Blood Brain Barrier ◽  
Measles Virus ◽  
Brain Barrier ◽  
Virus Antibody ◽  
Antibody Synthesis ◽  
Blood Brain ◽  
Multiple Sclerosis Patients

Measles virus antibody in aqueous humour of patients with uveitis associated with multiple sclerosis

The Lancet ◽  
1992 ◽  
Vol 339 (8795) ◽  
pp. 750-751 ◽  
Author(s):  
Etienne Bloch-Michel ◽  
Laurent Helleboid ◽  
Catherine Hill ◽  
Surge Koscielny ◽  
Elisabeth Dussaix
Keyword(s):  
Multiple Sclerosis ◽  
Measles Virus ◽  
Aqueous Humour ◽  
Virus Antibody

scholarly journals Decay of Passively Acquired Maternal Antibodies against Measles, Mumps, and Rubella Viruses

1999 ◽  
Vol 6 (6) ◽  
pp. 868-871 ◽  
Author(s):  
Corina Nicoara ◽  
Kristina Zäch ◽  
Daniel Trachsel ◽  
Daniel Germann ◽  
Lukas Matter
Keyword(s):  
Measles Virus ◽  
Fluorescent Antibody ◽  
Vaccine Dose ◽  
Optimal Time ◽  
Enzyme Linked Immunosorbent Assay ◽  
Age Group ◽  
Virus Antibody ◽  
Antibody Testing ◽  
Antibody Prevalence ◽  
Before School

ABSTRACT The decay of maternally derived antibodies to measles, mumps, and rubella viruses in Swiss infants was studied in order to determine the optimal time for vaccination. A total of 500 serum or plasma samples from infants up to 2 years of age were tested by enzyme-linked immunosorbent assay and fluorescent-antibody testing. The decline of antibody prevalence was slowest against the measles virus. By 9 to 12 months of age, only 5 of 58 (8.6%; 95% CI, 2.9 to 19.0) infants were antibody positive for the measles virus, and only 2 had levels above 200 mIU/ml. Mumps and rubella virus antibody seropositivity was lowest at 9 to 12 months of age with 3 of 58 (5.2%; 95% CI, 1.1 to 14.4) infants and at 12 to 15 months with 1 of 48 (2.1%; 95% CI, 0.1 to 11.1) infants, respectively. Concentrations of passively acquired antibodies decreased rapidly within the first 6 months of life. We observed no significant differences in antibody prevalence or concentration according to gender in any age group. In conclusion, MMR vaccination at 12 instead of 15 months of age could reduce the pool of susceptible subjects in infancy and support the efforts to eliminate these infections, particularly in combination with a second vaccine dose before school entry.

scholarly journals The epidemiology of measles in Poland: prevalence of measles virus antibodies in the population

2000 ◽  
Vol 125 (2) ◽  
pp. 385-392 ◽  
Author(s):  
W. JANASZEK ◽  
W. GUT ◽  
N. J. GAY
Keyword(s):  
Measles Virus ◽  
Virus Antibody ◽  
Serum Samples ◽  
High Coverage ◽  
Measles Elimination ◽  
Specific Igg ◽  
Catch Up ◽  
Low Levels ◽  
Measles Virus Antibodies ◽  
The Impact

WHO has adopted a goal of eliminating indigenous measles from the European Region by the year 2007. The strategy focuses on reducing the proportion of susceptible individuals in the population to low levels and maintaining these low levels of susceptibility. Routine vaccination against measles for children aged 13–15 months was introduced in Poland in 1975, and a second dose added in 1991. High coverage (> 95%) is achieved with both doses. In order to assess progress towards measles elimination in Poland, a serological survey was performed to evaluate the impact of vaccination on the susceptibility profile of population. Three thousand residual serum samples from individuals aged 1–30 years were collected from hospitals in six selected voivodeships (administration units) in Poland. These were tested for measles-specific IgG using a commercial ELISA. Overall 4% (120/3000) were negative for measles virus antibody. The highest proportion of negatives (8·2%) occurred among cohorts born 1977–81 – the only cohorts in which susceptibility exceeded the WHO targets. ‘Catch-up’ vaccination strategies should target these cohorts.

The effect of measles vaccination in rhesus monkeys (Macaca mulatta)

1982 ◽  
Vol 16 (3) ◽  
pp. 267-270 ◽  
Author(s):  
Judy A. MacArthur ◽  
P. G. Mann ◽  
V. Oreffo ◽  
G. B. D. Scott
Keyword(s):  
Macaca Mulatta ◽  
Rhesus Monkeys ◽  
Measles Virus ◽  
Haemagglutination Inhibition ◽  
Virus Antibody ◽  
Breeding Colony ◽  
Marked Rise ◽  
Measles Vaccination

30 rhesus monkeys ( Macaca mulatta), born into a breeding colony, received measles vaccination when aged between 3 and 26 months; 28 of them were re-vaccinated 5 to 7 months later. Measles virus antibody was measured by haemagglutination-inhibition at the time of each vaccination and again 3 to 6 weeks later. Only 2 out of 9 animals aged less than 6 months responded to vaccination, whereas 10 out of 14 older animals showed 4-fold or greater rises. Re-vaccination of the younger group when aged 8 to 10 months resulted in a marked rise in antibody.

Sign in / Sign up

Export Citation Format

Share Document